Pelthos Therapeutics Inc. (PTHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has a cash flow conversion efficiency ratio of -0.161x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.25 Million) by net assets ($38.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Pelthos Therapeutics Inc. market capitalisation for the company's overall valuation and market capitalisation.
Pelthos Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pelthos Therapeutics Inc. (PTHS) share price today for real-time trading data and today's change.
Pelthos Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their cash flow conversion efficiency. Review financial flexibility index of Pelthos Therapeutics Inc. to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Park Dental Partners, Inc. Common Stock
NASDAQ:PARK
|
0.039x |
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
0.056x |
|
MFS High Yield Municipal Closed Fund
NYSE:CMU
|
0.024x |
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TW:1762
|
0.028x |
|
Jinro Distillers Co. Ltd
KQ:018120
|
0.107x |
|
Federal Mogul Izmit Piston ve Pim Uretim Tesisleri AS
IS:FMIZP
|
0.067x |
|
Cartier Resources Inc
V:ECR
|
-0.014x |
|
MLG OZ Ltd
AU:MLG
|
0.297x |
Annual Cash Flow Conversion Efficiency for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Pelthos Therapeutics Inc. from 2021 to 2025. Also see PTHS total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $38.88 Million | $-22.59 Million | -0.581x | -127.22% |
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more